Shares of Marksans Pharma surged up to 14% on the back of its strongest quarter yet, with profit nearly tripling and revenues driven by record UK and European sales, as the drugmaker’s global footprint expands and cash reserves cross ₹1,000 crore.
Marksans Pharma shares surged on Wednesday after the drugmaker reported a sharp jump in quarterly earnings, with profit almost tripling and revenue rising strongly across several overseas markets. The stock rose as much as 14% to a fresh 52-week high of ₹320, extending a rally that has more than doubled the shares from their March low of ₹155.
According to the company’s latest results, consolidated net profit for the first quarter nearly tripled to ₹157.17 crore from ₹58.32 crore a year earlier. Revenue climbed 35.6% to ₹840.80 crore, while EBITDA more than doubled to ₹213.04 crore and the operating margin widened to 25.3% from 16.2%.
The strongest momentum came from the UK and Europe formulation business, which delivered its highest quarterly revenue on record at ₹356 crore, up nearly 75% from a year earlier. Marksans said new product launches, market share gains in the UK and a healthy order pipeline supported that performance. Its Netherlands-based unit, QliniQ, added ₹44 crore in revenue as the company continued to build out its European presence.
The US and North America division, which accounts for close to 45% of group revenue, grew 15.1% to ₹377 crore. Sales in Australia and New Zealand rose 53.7% to ₹88 crore, while the rest-of-world segment declined 36.8% because of delayed shipments to the Middle East, though it improved 6% from the previous quarter. Business Standard had reported earlier this year that Marksans was coming off a more mixed Q3 in FY26, when profit rose modestly and cash stood at ₹824.2 crore, highlighting how sharply the latest quarter improved sentiment.
Managing Director Mark Saldanha described the period as a strong start to the financial year and said the company’s cash balance crossed ₹1,000 crore for the first time, reaching ₹1,058 crore even after the acquisitions of QliniQ and ABCnow. That gives Marksans room to keep funding organic growth while remaining open to selective acquisitions. The company also said its FY26 net profit rose 9.8% to about ₹420 crore on revenue of roughly ₹2,951 crore, underlining a broader run of expansion before the latest quarterly acceleration.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
